The present invention relates to piperazine of formula (I) ##STR00001## wherein R represents halogen, C.sub.1-4 alkyl, trifluoromethoxy or trifluoromethyl; R.sub.1 is trifluoromethyl, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halogen or trifluoromethoxy; R.sub.2 is hydrogen, C.sub.1-4 alkyl or C.sub.2-6 alkenyl; R.sub.3 represents hydrogen or C.sub.1-4 alkyl; n and m are independently 0 or an integer from 1 to 3; and pharmaceutically acceptable salts and solvates thereof, process for their preparation and their use in the treatment of condition mediated by tachykinins and/or by selective inhibition of the serotonin reuptake transporter protein.